Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
Key facts
- Who runs it
- Henry Ford Health System
- Where
- Detroit, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 15 people enrolled
- Started
- 10 Jul 2018
- Ended
- 31 Mar 2026
- Type of study
- Interventional
- Treatments tested
- Watchfuf waiting
- Record updated
- 23 July 2026
- Why it stopped
- Lack of financial support
Who can take part
- Age
- 18 years to 95 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥ 18 years
- Diagnosis of rectal invasive adenocarcinoma
- Tumor in the low rectum lying < 4 cm from the anal verge
- Clinical stage T3/N0-N1M0
- Patients with low T2 who will need abdominal perineal resection are also eligible
Who cannot take part
- Other forms of cancer
- Age less than 18 years
- Tumors >= 4 cm from the anal verge
- Tumors of other clinical stages than listed above
Where in United States
- Ascension St. John HospitalDetroit, United States
About the trial
What the trial wants to find out
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.
The group in the trial
- Watchful WaitingTreatment being tested
Six cycles of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) will be administered every two weeks according to protocol. After a 3 week recovery period, this will be followed by conventional concurrent radiation and 5FU/capecitabine. Patients will be re-staged two to three weeks after completion of induction FOLFOX therapy to ensure no disease progression. The patients will be re-staged again at least 7-11 weeks post completion of nCRT. Patients with restaging results showing either complete or near complete response, will be allocated to "watchful waiting."
Treatment: Watchfuf waiting
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (Fluorouracil / Capecitabine)-Radio Therapy (CRT) With Watchful Waiting for Complete Responders
- Record updated
- 23 July 2026